{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:50:01Z","timestamp":1790117401580,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.7759\/cureus.107459","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:13:26Z","timestamp":1776777206000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Abdullah","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Polus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi R","year":"2020","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, et al.. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020, 369:m1590. 10.1136\/bmj.m1590","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: is the impairment to a patient's life cumulative?","volume":"24","author":"Kimball AB","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, et al.. Psoriasis: is the impairment to a patient's life cumulative?. J Eur Acad Dermatol Venereol. 2010, 24:989-1004. 10.1111\/j.1468-3083.2010.03705.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson T","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978, 157:238-44. 10.1159\/000250839","journal-title":"Dermatologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt A","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018, 55:379-90. 10.1007\/s12016-018-8702-3","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes JE","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018, 201:1605-13. 10.4049\/jimmunol.1800013","journal-title":"J Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian E","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al.. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022, 5:CD011535. 10.1002\/14651858.CD011535.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al.. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020, 156:258-69. 10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren RB","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al.. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021, 385:130-41. 10.1056\/NEJMoa2102388","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich K","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al.. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021, 385:142-52. 10.1056\/NEJMoa2102383","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 randomised controlled trial","volume":"397","author":"Reich K","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al.. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 randomised controlled trial. The Lancet. 2021, 397:487-498. 10.1016\/S0140-6736(21)00125-2","journal-title":"The Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon KB","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al.. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 2021, 397:475-486. 10.1016\/S0140-6736(21)00126-4","journal-title":"The Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren RB","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al.. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021, 184:50-9. 10.1111\/bjd.19341","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al.. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015, 162:777-84. 10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins JP","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, et al.. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012, 3:98-110. 10.1002\/jrsm.1044","journal-title":"Res Synth Methods"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani A","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, et al.. Graphical tools for network meta-analysis in STATA. PLoS One. 2013, 8:e76654. 10.1371\/journal.pone.0076654","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley RG","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014, 371:326-38. 10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017, 76:405-17. 10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich K","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al.. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017, 76:418-31. 10.1016\/j.jaad.2016.11.042","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa- 2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon KB","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al.. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa- 2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018, 392:650-661. 10.1016\/S0140-6736(18)31713-6","journal-title":"The Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich K","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al.. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet. 2019, 394:576-586. 10.1016\/S0140-6736(19)30952-3","journal-title":"The Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams R","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al.. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020, 11:1894. 10.3389\/fimmu.2020.01894","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485385-comparative-effectiveness-of-four-biologics-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:13:27Z","timestamp":1776777207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485385-comparative-effectiveness-of-four-biologics-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.107459","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}